10.1021/acsmedchemlett.9b00534.s001
Eric M. Gordon
Eric M.
Gordon
Matthew A. J. Duncton
Matthew A. J.
Duncton
Brian J. Wang
Brian J.
Wang
Longwu Qi
Longwu
Qi
Dazhong Fan
Dazhong
Fan
Xianfeng Li
Xianfeng
Li
Zhi-Jie Ni
Zhi-Jie
Ni
Pingyu Ding
Pingyu
Ding
Ruslan Grygorash
Ruslan
Grygorash
Eddy Low
Eddy
Low
Guijun Yu
Guijun
Yu
Jiawei Sun
Jiawei
Sun
Toward Orally Absorbed Prodrugs of the Antibiotic
Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part
2
American Chemical Society
2020
FDA
Gram-negative bacteria
Part 2 Aztreonam
monocyclic beta-lactam antibiotic
aztreonam
Novel Prodrugs
Sulfate Containing Drugs
Antibiotic Aztreonam
2020-01-10 14:39:35
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Toward_Orally_Absorbed_Prodrugs_of_the_Antibiotic_Aztreonam_Design_of_Novel_Prodrugs_of_Sulfate_Containing_Drugs_Part_2/11568711
Aztreonam, first
discovered in 1980, is an FDA approved, intravenous,
monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative
bacteria and is still used today. The oral bioavailability of aztreonam
in humans is less than 1%. Herein we describe the design and synthesis
of potential oral prodrugs of aztreonam.